RESEARCH ARTICLE

IL-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus

Camila Mareti Bonin-Jacob1,2*, Larissa Zаторрe Almeida-Lugo1, Marco Antonio Moreira Puga1,2*, Ana Paula Machado3, Caíla Tezelli Junqueira Padovani2, Mariana Calarge Noceti2, Alda Maria Teixeira Ferreira2, Carlos Eurico dos Santos Fernandes2, Júlio César Possati Resende4, Adriane Cristina Bovo5, Inês Aparecida Tozetti3

1 Postgraduate Program of Infectious and Parasitary Diseases from Medicine School, Federal University of Mato Grosso do Sul (UFMS), Campo Grande MS, Brazil, 2 Bioscience Institute, UFMS, Campo Grande, MS, Brazil, 3 Multicentric Program of Post-Graduation in Biochemistry and Molecular Biology of the Institute of Biosciences, UFMS, Campo Grande, MS, Brazil, 4 Department of Cancer Prevention, Barretos Cancer Hospital, Barretos, São Paulo, Brazil, 5 Department of Cancer Prevention, Barretos Cancer Hospital, Campo Grande, MS, Brazil

* These authors contributed equally to this work.
† MAMP, JCPR and ACB also contributed equally to this work.
marco.m.puga@gmail.com

Abstract

Persistent infection by high-risk human papillomavirus (HR-HPV) is the main cause of cervical cancer and its precursor lesions. While some cytokines help immune cells in virus clearance, others contribute to the persistence of infection and neoplastic progression. Here, the levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-6, IL-4, and IL-2 were quantified in the serum and exfoliated cervical cells (ECCs) of patients with HR-HPV, and the presence of IL-6+ cells was investigated in uterine cervix biopsies. Cytokine levels in the serum and ECCs of 26 HR-HPV DNA-positive patients and 18 HPV DNA-negative patients were measured using flow cytometry. Fifteen uterine cervix biopsy samples embedded in paraffin were subjected to immunohistochemical analysis for the detection of IL-6+ cells. HR-HPV levels in the serum and ECCs of 26 HR-HPV DNA-positive patients and 18 HPV DNA-negative patients were measured using flow cytometry. Fifteen uterine cervix biopsy samples embedded in paraffin were subjected to immunohistochemical analysis for the detection of IL-6+ cells. HR-HPV-positive patients showed increased IL-6 and IL-10 in the ECCs and serum, respectively. Compared with HPV DNA-positive patients, HPV DNA-negative patients had higher levels of IL-6 in ECCs. Patients with multiple infections of HPV had higher levels of IL-6 in their ECCs than those with a single infection. Immunostaining of uterine cervix biopsy samples revealed no differences in IL-6 expression between the different classes of histopathological lesions. However, differences were observed in the expression levels of IL-6 and IL-10 at the systemic and local levels in HR-HPV-positive patients without cervical lesions. Considering the functional characteristics of these cytokines, it can be inferred that such patients are prone to persistent HPV infection.

PLOS ONE | https://doi.org/10.1371/journal.pone.0248639  March 22, 2021 1 / 12

OPEN ACCESS

Citation: Bonin-Jacob CM, Almeida-Lugo LZ, Puga MAM, Machado AP, Padovani CTJ, Noceti MC, et al. (2021) IL-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus. PLoS ONE 16(3): e0248639. https://doi.org/10.1371/journal.pone.0248639

Editor: Magdalena Grce, Rudjer Boskovic Institute, CROATIA

Received: July 30, 2020
Accepted: March 3, 2021
Published: March 22, 2021

Copyright: © 2021 Bonin-Jacob et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. The cytokine results of each sample are uploaded to figshare (10.6084/m9.figshare.13550510).

Funding: This study received financial supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant number: 406148/2016-3) and financed in part by Fundação Universidade Federal de Mato Grosso do Sul
Introduction

Cervical cancer is the fourth most common cancer among women worldwide [1]. Persistent infection with high-risk human papillomavirus (HR-HPV), especially HPV16 and HPV18, is mainly responsible for the development of cervical cancer and its precursor lesions, including squamous intraepithelial lesion (SIL) [2, 3]. HPV infection in the female genital tract has a transient pattern, and most immunocompetent individuals (70–90%) can eliminate the virus within 12 to 24 months of diagnosis [4, 5]. However, about 10% of patients fail to show viral clearance and remain infected [3].

Viral clearance and control of the progression of virus-induced lesions are mediated through an active immune response in immunocompetent individuals. In particular, the cell-mediated immune response plays an important role in the control of both HPV and cervical lesions [6, 7]. During this process, the cytokines secreted by both T cells and accessory cells such as keratinocytes are extremely important for the regulation and control of cellular immunity. Some cytokines help the cellular immune response eliminate and control HPV infection, including interferon (IFN)-γ, which enhances the expression of the major histocompatibility complex (MHC) in tumor cells and inhibits angiogenesis [8] and tumor necrosis factor (TNF)-α, which exhibits antitumor properties and inhibits the growth of some cell lineages transformed by HPV [9]. Other cytokines, such as interleukin (IL)-6, IL-10, and IL-17, have been associated with the persistence of HPV infection and the occurrence of favorable conditions to facilitate the development of neoplastic lesions [10–13]. Moreover, the autocrine secretion of IL-4 promotes increased survival and resistance to cell death in CD133+ cervical cancer stem cells (CSC) [14].

Because HPV infection is restricted to the epithelium and both local and systemic immunity may be related to virus clearance or persistence of HPV infection, the levels of cytokines IFN-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2 were measured in the exfoliated cervical cells (ECCs) and serum of patients positive for HR-HPV DNA and negative for HPV DNA, a majority of which do not have cervical lesions. The expression of IL-6 in cervical stromal cells was also evaluated to better understand the behavior of these cytokines during HR-HPV infection.

Materials and methods

Study population

The samples used in this study were obtained from a previous study in which 410 women older than 18 years were subjected to identification and genotyping of HPV as well as the identification of the presence of co-infections [15]. The case group was composed of serum and exfoliated cervical cell (ECC) samples from 26 of 410 women positive for HR-HPV DNA selected using non-probability sampling for convenience. The control group was composed of serum and exfoliated cervical cell (ECC) samples from 18 women negative for HPV, randomly selected from the group of women negative for HPV (n = 373/410). HPV genotype assays were performed via polymerase chain reaction using PGMY primers, followed by type-specific PCR (TS-PCR) and restriction fragment length polymorphism (RFLP) S1 and S2 Tables. Samples that were not genotyped through TS-PCR and RFLP were sequenced using an ABI-Prism 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) [15].

None of the patients included in the present study had undergone a hysterectomy or had exposure to immunosuppressive drugs, and none were pregnant or in their menstrual period. These patients were also negative for Chlamydia trachomatis and Trichomonas vaginalis DNA, anti-human immunodeficiency virus (HIV) and anti-Treponema pallidum, and circulating hepatitis B virus surface antigen (HBsAg) [15] to exclude any systemic and local co-infections.
in the uterine cervix that could influence the cytokine levels. In addition to serum and ECC samples, we also used samples of cervical biopsies from women positive for HR-HPV with high-grade squamous intraepithelial lesion (HSIL), low-grade squamous intraepithelial lesion (LSIL), and cervical cancer (CC) lesions from previous studies [15, 16].

All women who agreed to participate in this study signed an informed consent form. This study was approved by the Research Ethics Committee of the Federal University of Mato Grosso do Sul and the Fundação Pio XII of Barretos, SP, under protocols n° 1468457 and 1635895, respectively.

Acquisition of samples
In this study, samples of ECC and serum were used to measure the expression levels of cytokines IFN-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2, and samples of uterine cervix biopsies were used to identify the presence of IL-6 through immunohistochemistry. All samples used in this study were obtained from previous studies [15, 16].

Briefly, the ECC samples for the measurement of cytokines and identification of HPV were collected using disposable specula and soft endocervical brushes with protected tips, as described in a previous study [15]. Serum samples for cytokine measurement were collected via venipuncture. Blood samples were processed to obtain sera, aliquoted, and stored at 80°C until analysis. Samples of uterine cervix biopsies obtained from women positive for HR-HPV DNA through pathological examination of a low-grade squamous intraepithelial lesion (LSIL) (n = 1) and a high-grade squamous intraepithelial lesion (HSIL) (n = 1), and were used for immunohistochemical (IHC) analysis [15]. In addition to these samples, others with pathological classifications such as LSIL (n = 4), HSIL (n = 5), and cervical cancer (n = 4) were included from previous studies [16] to obtain parameters for the evaluation of IL-6 in samples with different degrees of lesion severity.

Cytokine measurements
The levels of cytokines were determined in the serum and ECCs from 26 patients positive for HR-HPV DNA and 18 patients negative for HPV DNA. The concentrations of IFN-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2 cytokines were determined using a Cytometric Bead Array (CBA) Human Th1/Th2/Th17 Cytokine Kit (BD Biosciences, San Jose, CA, USA). Standards, beads, samples, and protocols for the flow cytometer setup and data acquisition were performed according to the manufacturer’s instructions. Samples were evaluated using a FACS Canto II Flow Cytometer (BD Biosciences, San Jose, CA, USA) and analyzed with the FCAP Array software V. 3.0 (Becton Dickinson, Franklin Lakes, NJ, USA). The results were based on standard concentration curves and expressed as picograms per milliliter (pg/mL).

Immunohistochemistry
IHC analysis was performed on paraffin-embedded sections to identify the presence of IL-6-positive cells. Immunohistochemical staining was performed following antigen retrieval by pressure cooking for 1 min in 10 mM sodium citrate buffer (pH = 6). IL-6 was detected via incubation with a primary IL-6 antibody, IgG2a (ab9324, Abcam, Cambridge, UK) at a 1:500 dilution for 1 h at room temperature. Detection of immunohistochemical signals was performed using a HiDef Detection Kit (954D-30; Cell Marque, Rocklin, CA, USA) according to the manufacturer’s instructions. Staining was performed with the chromogen 3, 3-diaminobenzidine (EP-12-20542- EasyPath, São Paulo, SP, Brazil) for 10 min. The slides were counterstained with hematoxylin for 20 s. Appropriate positive (with primary antibody) and negative (no primary antibody) controls were included using human tonsil sections.
For sections subjected to immunohistochemistry, images were acquired using a Moticam 2300 digital camera (Motic, Hong Kong, China) attached to a Nikon Eclipse E200 microscope (Nikon, Tokyo, Japan), and were processed using Motic Images Plus 2.0 software (Motic, Hong Kong, China). Images (1024 × 768 pixels) were obtained from 10 randomly selected fields for each slide at 400× magnification without any knowledge of the histopathological lesions. The size of features in the images was determined using ImageJ software 1.47 (National Institutes of Health, Bethesda, MD, USA) and the freehand line tool. Images that were 1024 × 768 pixels corresponded to 170.67 × 128.00 μm. Using the cell counter plugin of ImageJ software, the number of immunostained cells was determined for each image, and the average number of immunostained cells per mm² area was determined [17].

**Statistical analysis**

The detection limit values provided in the Cytometric Bead Array (CBA) Human Th1/Th2/Th17 Cytokine Kit (IFN-gamma: 3.7, TNF: 3.8, IL-10: 4.5, IL-6: 2.4, IL-4: 4.9, and IL-2: 2.6) were used for samples whose concentrations were not determined.

The values of cytokine levels are expressed as the median and interquartile range (IQR). Data were analyzed using non-parametric tests. To test the significance of the differences between HR-HPV⁺ and HPV⁻ and single and multiple infections, the Mann-Whitney U-test was used. The Wilcoxon signed-rank test was used to analyze the groups of HR-HPV DNA-positive samples comprising the serum and exfoliated uterine cervix samples from the same patient. The Kruskal-Wallis test was used to compare histopathological and immunohistochemical findings. The results were considered significant at p < 0.05. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA).

**Results**

The characteristics of the study participants are listed in Table 1. The HR-HPV genotypes identified were HPV 59 (38.5%, 10/26), HPV 45 (19.2%, 5/26), HPV 18 (15.4%, 4/26), HPV 16 (11.5%, 3/26), HPV 52 (11.5%, 3/26), HPV 66 (11.5%, 3/26), HPV 33 (3.8%, 1/26), HPV 31 (3.8%, 1/26), HPV 26 (3.8%, 1/26), HPV 30 (3.8%, 1/26), HPV 53 (3.8%, 1/26), HPV 69 (3.8%, 1/26), and HPV 82/85 (3.8%, 1/26). The genotypes HPV6/11 (42.3%, 11/26) and HPV32 (3.8%, 1/26) were identified as LR-HPV. Of all the samples, 53.8% (14/26) were classified as single infections caused by only one type of HR-HPV. Multiple infections or infections with more than one viral type were detected in 46.2% (12/26) of the samples [15].

**Table 1. Characteristics of the study participants (n = 44).**

| Characteristics | HR-HPV DNA⁺ | HPV DNA⁻ |
|-----------------|-------------|-----------|
| Age             |             |           |
| < 40 years old  | 9 (34.6)    | 8 (44.4)  |
| 40–49 years old | 7 (26.9)    | 3 (16.7)  |
| > 50 years old  | 10 (38.5)   | 7 (38.9)  |
| Cytology        |             |           |
| ASC-US          | 4 (15.4)    | 0 (0.0)   |
| NILM            | 21 (80.8)   | 18 (100.0) |
| LSIL            | 1 (3.8)     | 0 (0.0)   |

ASC-US, atypical cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.

[10.1371/journal.pone.0248639.t001](https://doi.org/10.1371/journal.pone.0248639.t001)

---

PLOS ONE | https://doi.org/10.1371/journal.pone.0248639 March 22, 2021 4 / 12
The levels of cytokines IFN-γ, TNF-α, IL-10, IL-6, IL-4, and IL-2 were quantified (pg/mL) in the serum and ECCs of 26 patients positive for HR-HPV DNA (mean age: 44.7 years) and 18 patients negative for HPV DNA (mean age: 43.6 years) as shown in the Supporting Information–Cytokine levels (DOI 10.6084/m9.figshare.13550510).

The comparison of cytokine levels in the ECCs and serum of patients positive for HR-HPV revealed a significantly higher concentration of IL-6 in ECCs (p = 0.0135) and IL-10 in the serum (p = 0.0298). The differences in the concentrations of other cytokines were not significant (Table 2). To verify whether HPV influences cytokine secretion, the serum and ECC levels of cytokines were compared between HR-HPV-positive and HPV-negative patients. No significant differences were observed in the blood cytokine levels between the two groups (Table 3). However, IL-6 levels were higher in the ECC samples from HPV-negative patients (p = 0.0132) (Table 3).

To investigate whether a simple infection (by a single viral genotype) or multiple infections (by more than one viral genotype) influences the cytokine profile in the serum and ECCs, the

### Table 2. Cytokine levels in the Exfoliated Cervical Cells (ECC) and serum of HR-HPV DNA-positive patients (n = 26).

| Cytokines | Serum median (25th-75th) | ECC median (25th-75th) | Value of p |
|-----------|--------------------------|------------------------|------------|
| IFN-γ     | 3.7 (3.7–3.9)            | 3.7 (3.7–3.7)          | 0.1952     |
| TNF       | 4.2 (3.8–4.7)            | 4.1 (3.8–4.4)          | 0.4029     |
| IL-10     | 4.5 (4.5–5.1)            | 4.5 (4.5–4.5)          | 0.0247     |
| IL-6      | 3.4 (2.4–4.4)            | 4.6 (2.4–30.2)         | 0.0135     |
| IL-4      | 4.9 (4.9–4.9)            | 4.9 (4.9–4.9)          | 0.3125     |
| IL-2      | 2.6 (2.6–2.6)            | 2.6 (2.6–2.6)          | 0.8750     |

Note: The results are expressed as the median and interquartile range (25th-75th). Wilcoxon signed-rank test was performed. Statistical significance was set at p < 0.05. ECC exfoliated cervical cells.

https://doi.org/10.1371/journal.pone.0248639.t002

### Table 3. Cytokine levels in the Exfoliated Cervical Cells (ECC) and serum of HR-HPV DNA-positive and HR-HPV DNA-negative patients.

| Sample | Cytokines | HPV DNA negative (n = 18) median (25th-75th) | HR-HPV DNA positive (n = 26) median (25th-75th) | Value of p |
|--------|-----------|---------------------------------------------|-----------------------------------------------|------------|
| Serum  | IFN-γ     | 3.7 (3.7–3.7)                              | 3.7 (3.7–3.9)                                 | 0.1030     |
|        | TNF       | 3.8 (3.8–4.2)                              | 4.2 (3.8–4.7)                                 | 0.0547     |
|        | IL-10     | 4.5 (4.5–4.5)                              | 4.5 (4.5–5.1)                                 | NC         |
|        | IL-6      | 3.6 (2.4–4.5)                              | 3.4 (2.4–4.4)                                 | 0.9518     |
|        | IL-4      | 4.9 (4.9–4.9)                              | 4.9 (4.9–4.9)                                 | 0.9827     |
|        | IL-2      | 2.9 (2.6–2.6)                              | 2.9 (2.6–2.6)                                 | 0.8484     |
| ECC    | IFN-γ     | 3.7 (3.6–3.7)                              | 3.7 (3.7–3.7)                                 | 0.3289     |
|        | TNF       | 4.0 (3.9–4.3)                              | 4.1 (3.8–4.4)                                 | 0.8658     |
|        | IL-10     | 4.5 (4.5–4.5)                              | 4.5 (4.5–4.5)                                 | 0.6842     |
|        | IL-6      | 33.4 (9.4–76.6)                            | 4.6 (2.4–30.2)                                | 0.0132     |
|        | IL-4      | 4.9 (4.9–4.9)                              | 4.9 (4.9–4.9)                                 | 0.8484     |
|        | IL-2      | 2.6 (2.6–2.6)                              | 2.6 (2.6–2.6)                                 | 0.1612     |

Note: The results are expressed as the median and interquartile range (25th-75th). The Mann-Whitney U-test was performed, and statistical significance was set at p < 0.05. ECC, exfoliated cervical cells. NC, not calculated.

https://doi.org/10.1371/journal.pone.0248639.t003
cytokine levels were compared between both sites in these two groups (patients with simple infection and multiple infections). IL-6 levels were higher in the ECCs of patients with multiple infections \( (p = 0.0380) \) than those patients with a simple infection (Table 4), although the levels were lower than those detected in patients negative for HPV DNA (Table 3). The concentrations of other cytokines were similar between the two groups. Evaluation of serum samples showed no significant differences in the concentrations of cytokines between the different groups based on the infection type (Table 4).

In the analysis of cytokine levels in serum and ECC samples between different age groups, we found that IL-6 was significantly higher in serum samples from positive HR-HPV DNA patients older than 50 years \( (p = 0.0195) \) than in the group under 40 years old (median and IQR for IL-6: 4.4, 3.4–5.6; 3.4, 2.5–3.9, respectively).

**Cells expressing IL-6 in uterine cervix lesions**

To confirm the role of IL-6 in the cervical microenvironment of patients infected with HR-HPV, samples with different degrees of cervical lesions were subjected to immunohistochemistry analysis. Immunostaining for IL-6 was performed on 15 samples from HR-HPV-positive uterine cervix biopsies, two of which were obtained from the patients at the Hospital de Amor de Campo Grande (Barretos Cancer Hospital), Campo Grande, MS, and 13 were derived from a previous study [16]. Among the 15 samples, 5, 6, and 4 were classified as LSIL, HSIL, and cervical cancer, respectively.

In total, 150 images were acquired and analyzed to count cells expressing IL-6 in the stromal samples of uterine cervix biopsies (Fig 1). The mean number of IL-6+ cells varied from 2883.8 to 6252.9 cells/mm², but there was no significant difference among the histopathological classes (Fig 1).

**Discussion**

The results of this study demonstrate the differences in the levels of IL-6 and IL-10 among patients positive for HR-HPV, as well as the difference in their immune response at the local and systemic levels. IL-6 levels were elevated in the ECCs from HPV-negative patients,
suggestive of its continuous stimulation at this site owing to the existing microbiota with pro-inflammatory activities [18]. Furthermore, IL-6 concentration in the ECCs of HR-HPV-positive patients and those with multiple infections was high but lower than that reported in HPV-negative patients. IL-10 expression may be responsible for the suppression of various cytokines, including IL-6 [19]. The level of this immunosuppressive cytokine was systemically high in HR-HPV-positive patients. IHC analysis for the expression level of IL-6 in situ revealed no differences between samples with different degrees of histopathological lesions.

Persistent HR-HPV infection is an important factor in the development of cervical cancer [2, 3, 20]. Although HPV16 and HPV18 are the genotypes most closely related to cervical cancer, other genotypes have also been associated with cancer and its precursor lesions and may vary according to age and geographic region [3, 20, 21].

Global epidemiological studies have indicated 18 different oncogenic high-risk HPV genotypes (HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, and HPV82) that are associated with cervical cancer [21, 22]. HPV69, HPV30, and HPV85 were regarded as highly oncogenic in the present study, although they were classified as possibly oncogenic [23].

Since the immune response is essential for the elimination of HPV, and age and hormonal changes could influence the immune system and affect the mechanisms of viral elimination [24], cytokine level analysis may be useful to better understand the changes and deviations in the immune response caused by HPV infection at the systemic and local levels. In our study, we found that the concentration of IL-6 in serum samples from HR-HPV-positive patients was higher in the group of women over the age of 50, when compared to those under the age of 40 (p = 0.0195), suggesting that in this group, there may be a greater stimulus for the production of this cytokine at the systemic level. However, additional studies are needed to assess whether this increase may be due to persistent HR-HPV infection or whether it is associated with possible hormonal variations and other aging stimuli.
Several studies have investigated the relationship between cervical cancer and its precursor lesions and the levels of cytokines present in the serum, cervical secretions, and uterine cervix biopsies [11, 13, 25, 26]. However, the expression of cytokines analyzed in the serum and ECC samples came mostly from patients without cervical lesions, which allowed us to evaluate the relationship between the host immune system and the virus.

The comparison of IL-6 levels in the serum and ECCs of HR-HPV-positive patients revealed higher levels of IL-6 in the ECCs, suggesting that IL-6 is mainly produced at the site of infection and that the immune response in the same patient changes at the systemic level. However, the level of IL-6 was 8.3-fold higher in the ECCs of HPV-negative patients. In a study evaluating IL-6 concentration in the cervicovaginal washings of patients with cervical cancer and cervical intraepithelial neoplasia (CIN) and healthy controls, higher IL-6 levels were observed in patients with cervical cancer than in healthy subjects, indicating a relationship between IL-6 levels and the pathogenesis and severity of cervical neoplasia [13]. Unlike in the present study, these samples were obtained from HPV-positive patients diagnosed with cervical cancer or CIN. This may explain the higher concentration of IL-6 at this site [27], as stromal cells or neoplastic cells tend to release more IL-6, IL-8, and vascular endothelial growth factor (VEGF) at sites of intense inflammation (chronic infection and cervical lesions) [27–29]. Zanotta et al. [11] evaluated cytokine levels in the cervicovaginal fluid of young patients with and without cervical lesions infected with HR-HPV and observed an association between IL-6 expression and HR-HPV infection. These authors also reported a significant increase in IL-6 expression in samples with cytological abnormalities compared with HR-HPV-positive and -negative samples without cytological abnormalities. Thus, HR-HPV may influence IL-6 production during the early inflammatory response.

The expression of IL-6 was observed to be higher in ECCs than in the serum. IL-6 is capable of promoting the growth of cervical tumor cells [30] and is involved in tumor angiogenesis through the regulation of VEGF during the early stages of cervical cancer [27, 31]. Furthermore, IL-6 is associated with the development of HPV-induced cervical lesions [13, 27]. Hence, IHC analysis was performed to detect the expression of IL-6 in the stroma from samples with different degrees of cervical lesions. However, no relevant changes were observed. Other authors that assessed the levels of IL-6 in cervical cancer tissues and adjacent non-tumor tissues found higher expression in cervical cancer tissues [27, 32], suggesting its role as a biomarker for the prognosis and therapy of cervical cancer [32].

As IL-6 may induce the differentiation of activated B cells into antibody-producing cells [33] and CD8+ T cells into cytotoxic cell types [34], its presence in the cervix of healthy individuals is of great importance for the elimination and control of various microorganisms. The presence of IL-6 at high concentrations in the exfoliated uterine cervix of HPV-negative patients, as observed in the present study, may be due to the constant stimuli at this site from the naturally colonizing microorganisms [35, 36]. IL-6 concentration at this site remained high in HR-HPV-positive patients but was lower in HPV-negative patients. This observation may be related to the immunosuppressive stimuli produced by HPV, such as the induction of IL-10 production by different cell types in the infected microenvironment [17, 37] or even by systemic IL-10 [38]. This study revealed a higher concentration of IL-10 in the serum than in the cervix of HPV-positive patients. In the serum, IL-10 may play a role in controlling IL-6 production and subsequently decreasing its concentration in the blood. However, the suppression triggered by systemic IL-10 was insufficient to completely inhibit the production of IL-6 in the cervix.

IL-10 is capable of modulating both innate and adaptive immunity, primarily because it exerts anti-inflammatory effects, and is therefore essential for maintaining homeostasis of the immune response [39]. Upon overproduction, IL-10 may impair the immune response by...
inhibiting the production of IL-2, IFN-γ, and IL-12, which are essential for virus and tumor cell clearance. Some authors have associated the presence of high levels of IL-10 with persistent HPV infection and the progression of cervical lesions induced by this virus [12,40]. However, in the present study, no association was observed between cytokine levels and the presence or absence of HPV infection. In HR-HPV-positive patients, a difference in cytokine levels was noted at the site of analysis (local or systemic). Thus, HPV infection, although considered restricted to the epithelium, could induce the systemic production of IL-10.

Studies have shown that cervical infections caused by more than one type of HPV are frequently reported [41,42], as infections by a specific virus type do not reduce the likelihood of infection by other phylogenetically related types [43]. In the present study, 12 patients with multiple infections were detected, and their cytokine profiles were analyzed at the systemic and local levels and compared with those of the patients with simple infection. IL-6 expression was significantly higher in the ECCs of patients with multiple infections. In these patients, simultaneous infection with several viral genotypes may induce a more vigorous local immune response compared to patients infected by a single viral genotype, consistent with the increase in IL-6 expression level in the ECCs. Unfortunately, in our study, it was not possible to form a group of patients with multiple infections caused only by HR-HPV, excluding any other type of LR-HPV that may interfere with these results.

The data of this study on IL-6 and the data published [15] about IL-17 in the same population show that HPV plays an important role in immune response modulation. The induction of Th17 responses producing IL-17 causes viral persistence and difficulty in the removal of infected cells by inhibiting cytotoxic T cell function and apoptotic cell death. IL-6 is a major cytokine that promotes the induction of pathogenic Th17 responses [44]. The effects of both cytokines IL-6 and IL-17 have a major impact on several chronic diseases, such as chronic viral infection and cancer development. An elevation in the expression of these cytokines can play a critical role in establishing viral persistence and the development of cervical cancer.

In conclusion, this study provides evidence that IL-6 expression was significantly increased in ECCs (p = 0.0135) during HPV infection. Regarding IL-10, although the difference in concentration between the two sites (ECC and serum) was not very high, it was significant, showing that there were differences in the expression of this cytokine at the systemic and local levels. This finding, in addition to the fact that IL-6 and IL-10 are related to the development of HPV-induced cervical lesions and suppression of the immune cells that are important in virus elimination, suggests that these patients are at a higher risk of persistent HPV infection. Further studies are warranted to monitor the development of infections in these patients.

Supporting information

S1 Table. Primes used in pool PGMY-PCR detection according to fragment size, sequence, annealing region and melting temperature (Tm).

S2 Table. Primes used in TS-PCR genotyping according to fragment size, sequence, annealing region and melting temperature (Tm).

Acknowledgments

The authors are grateful to all the women who participated in the study and to the gynecologists and nurses from the Department of Prevention of Barretos Cancer Hospital.
Author Contributions

**Conceptualization:** Camila Mareti Bonin-Jacob, Cacilda Tezelli Junqueira Padovani, Inês Aparecida Tozetti.

**Data curation:** Camila Mareti Bonin-Jacob.

**Formal analysis:** Camila Mareti Bonin-Jacob, Carlos Eurico dos Santos Fernandes, Inês Aparecida Tozetti.

**Funding acquisition:** Inês Aparecida Tozetti.

**Investigation:** Camila Mareti Bonin-Jacob, Larissa Zatorre Almeida-Lugo, Marco Antonio Moreira Puga, Ana Paula Machado, Cacilda Tezelli Junqueira Padovani, Mariana Calarge Noceti, Júlio César Possati Resende, Adriane Cristina Bovo, Inês Aparecida Tozetti.

**Methodology:** Camila Mareti Bonin-Jacob, Larissa Zatorre Almeida-Lugo, Marco Antonio Moreira Puga, Ana Paula Machado, Cacilda Tezelli Junqueira Padovani, Mariana Calarge Noceti, Alda Maria Teixeira Ferreira, Carlos Eurico dos Santos Fernandes.

**Supervision:** Camila Mareti Bonin-Jacob, Inês Aparecida Tozetti.

**Validation:** Camila Mareti Bonin-Jacob.

**Writing – original draft:** Camila Mareti Bonin-Jacob, Cacilda Tezelli Junqueira Padovani, Inês Aparecida Tozetti.

**Writing – review & editing:** Camila Mareti Bonin-Jacob, Larissa Zatorre Almeida-Lugo, Marco Antonio Moreira Puga, Ana Paula Machado, Cacilda Tezelli Junqueira Padovani, Mariana Calarge Noceti, Alda Maria Teixeira Ferreira, Carlos Eurico dos Santos Fernandes, Júlio César Possati Resende, Adriane Cristina Bovo, Inês Aparecida Tozetti.

References

1. Brunni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 27 July 2017. [15 de Agosto de 2018].

2. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al.; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. Vaccine 31(Suppl 6): G1–G31.

3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370:890–907. https://doi.org/10.1016/S0140-6736(07)61416-0 PMID: 17826171

4. Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1700 women referred to colposcopy in Oklahoma. Int. J. Cancer 2009; 124:964–969. https://doi.org/10.1002/ijc.23969 PMID: 19030188

5. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–8. https://doi.org/10.1056/NEJM199802123380703 PMID: 9459645

6. Paaso AHM, Koskimaa MJ, Welter S, Grénman K, Syrjänen SH, van der Burg, et al. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years. J. Transl. Med. 2015; 13:163. https://doi.org/10.1186/s12967-015-0498-9 PMID: 25990808

7. Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 2014; 5:5317. https://doi.org/10.1038/ncomms6317 PMID: 25354725

8. Alshaker HA, Mataika K. Z. IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumor. Cancer Cell Int 2011; 11:33. https://doi.org/10.1186/1475-2867-11-33 PMID: 21943203
9. Scott M, Nakagawa M, Moscick AB. Cell-mediated immune response to human papillomavirus infection. Clin Diag Lab Immunol 2001; 8:209–20. https://doi.org/10.1128/CDLI.8.2.209-220.2001 PMID: 11238198
10. Xue J, Wang Y, Chen C, Zhu X, Zhu H, Hu Y. Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection. Cancer Med 2018; 7:297–306. https://doi.org/10.1002/cam4.1279 PMID: 29277958
11. Zanotta N, Tornesello ML, Annunziata C, Stellato G, Buonaguro FM, Comar M. Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. PLoSOne. 2011; 11:e0151851. https://doi.org/10.1371/journal.pone.0151851 PMID: 26990868
12. Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol 2014; 5:753–63. https://doi.org/10.3892/wjco.v5.i4.753 PMID: 25302175
13. Tjong MY, van der Vange N, ten Kate FJ, Tjong-A-Hung SP, ter Schegget J, Burger MP, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol 1999; 73:285–91. https://doi.org/10.1006/gyno.1999.5356 PMID: 10329048
14. Liu CT, Xin Y, Tong CY, Li B, Bao HL, Zhang CY, et al. Production of interleukin-4 in CD133+ cervical cancer stem cells promotes resistance to apoptosis and initiates tumor growth. Mol Med Rep. 2016 Jun; 13: 5068–5076. https://doi.org/10.3892/mmr.2016.5195 PMID: 27121303
15. Maretli Bonin C, Zatorre Almeida-Lugo L, Rodrigues Dos Santos A, Tezelli Junqueira Padovani C, Silva Pina AF, Teixeira Ferreira AM, et al. Interleukin-17 expression in the serum and exfoliated cervical cells of patients infected with high-risk oncogenic human papillomavirus. Cytokine 2019; 120:92–98. https://doi.org/10.1016/j.cyto.2019.04.008 PMID: 31054481
16. Bonin CM, Padovani CTJ, da Costa IP, Ávila LS, Ferreira AMT, Fernandes CES. Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection. J Med Virol 2018; https://doi.org/10.1002/jmv.25312 PMID: 30192406
17. Prata TT, Bonin CM, Ferreira AM, Padovani CT, Fernandes CE, Machado AP, et al. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology 2015; 148:113–21. https://doi.org/10.1111/imm.12487 PMID: 26059389
18. Lieberman JA, Moscicki AB, Sumerel JL, Ma Y, Scott ME. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunosassay method and assessment of correlates. Clin Vaccine Immunol. 2008; 15:49–54. https://doi.org/10.1128/CVI.00216-07 PMID: 17978011
19. Takeshita S, Gage JR, Kishimoto T, Vredevoe DL, Martinez-Maza O. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. J. Immunol 1996; 156:2591. PMID: 8786324
20. Li N, Franceschi S, Howell-Jones R, Snijders Pj, Clifford Gm. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927–35. https://doi.org/10.1002/ijc.25396 PMID: 20473886
21. de Sanjose S, Quint WG, Alemay L, Geraets DT, Lloveras B, Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048–56. https://doi.org/10.1016/S1470-2045(10)70230-8 PMID: 20952254
22. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–27. https://doi.org/10.1056/NEJMoa021641 PMID: 12571259
23. International Agency for Research on Cancer (IARC). IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Biological Agents. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100B.) Human Papillomaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK304347/
24. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Ver Immunol 2013; 13:875–87. https://doi.org/10.1038/nri3547 PMID: 24157572
25. Ali KS, Ali HY, Jubaerl JM. Concentration levels of IL-10 and TNFα cytokines in patients with human papilloma virus (HPV) DNA+ and DNA- cervical lesions. J Immunotoxicol 2012; 9:168–72. https://doi.org/10.3109/15476791.2011.642419 PMID: 22471745
26. Vidal AC, skaar D, Maguire R, Dodor S, Musselwhite LW, Bartlett JA, et al. IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes. Infect Agent Cancer 2015; 10:10.
27. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001; 82:49–56.

28. Ren C, Cheng X, Lu B, Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer 2013; 49:3889–99. https://doi.org/10.1016/j.ejca.2013.07.140 PMID: 23995305

29. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001; 10:1021–7. PMID: 11588127

30. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993; 50:15–9. https://doi.org/10.1006/gyno.1993.1156 PMID: 8349158

31. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22:1517–27. https://doi.org/10.1038/sj.onc.1206226 PMID: 12629515

32. Song Z, Lin Y, Ye X, Feng C, Lu Y, Yang G, et al. Expression of IL-1α and IL-6 is associated with progression and prognosis of human cervical cancer. Med Sci Monit 2016; 22:4475–4481. https://doi.org/10.12659/msm.898569 PMID: 27866212

33. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res 2017; 179:168–182. https://doi.org/10.1016/j.trsl.2016.07.004 PMID: 27477083

34. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, et al. The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization? PLoS One 2014; 9: e105998. https://doi.org/10.1371/journal.pone.0105998 PMID: 25148517

35. Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells, Nat Rev Immunol 2010; 10:170–81. https://doi.org/10.1038/nri2711 PMID: 20154735

36. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998; 16:152–9. https://doi.org/10.3109/07357909809050029 PMID: 9541628

37. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J. Exp. Med. 2009, 206:313–328. https://doi.org/10.1084/jem.20082030 PMID: 19204109